Premium
The role of autologous haemopoietic stem cell transplantation in the treatment of autoimmune disorders
Author(s) -
Rebeiro P.,
Moore J.
Publication year - 2016
Publication title -
internal medicine journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.596
H-Index - 70
eISSN - 1445-5994
pISSN - 1444-0903
DOI - 10.1111/imj.12944
Subject(s) - medicine , scleroderma (fungus) , cyclophosphamide , transplantation , immunosuppression , multiple sclerosis , hematopoietic stem cell transplantation , clinical trial , autoimmune disease , autologous stem cell transplantation , stem cell , immunology , multiple myeloma , immune system , oncology , disease , chemotherapy , inoculation , biology , genetics
Autologous haemopoietic stem cell transplantation (HSCT) has been used for over 30 years for malignant haematological diseases, such as myeloma and lymphoma, with considerable success. More recently this procedure has been adopted as a form of high dose immunosuppression in selected patients with autoimmune diseases that are resistant to conventional therapies. Animal models have previously outlined the rationale and validity of HSCT in patients with these non‐malignant, but in many cases, life‐threatening conditions. Recent data have that deletion of putative autoreactive immune clones with reconstitution of a thymic driven, tolerant immune system occurs in HSCT for auto‐immune patients. Two randomised control trials have confirmed that HSCT is superior to monthly cyclophosphamide in systemic sclerosis with a highly significant disease free and overall survival benefit demonstrated in the Autologous Stem cell Transplantation International Scleroderma trial. Over 2000 patients worldwide with autoimmune conditions have been treated with HSCT – the commonest indications being multiple sclerosis (MS) and systemic sclerosis. Encouraging relapse free survival of 70–80% at 4 years, in heavily pre‐treated MS patients, has been demonstrated in Phase II trials. A Phase III trial in MS patients who have failed interferon is currently accruing patients. Future challenges include improvements in safety of HSCT, particularly in cardiac assessment of systemic sclerosis patients, cost–benefit analyses of HSCT compared to standard therapy and establishment of centres of excellence to continue to enhance the safety and benefit of this exciting new therapy.